Copyright
©The Author(s) 2022.
World J Virol. Sep 25, 2022; 11(5): 221-236
Published online Sep 25, 2022. doi: 10.5501/wjv.v11.i5.221
Published online Sep 25, 2022. doi: 10.5501/wjv.v11.i5.221
Figure 2 Preclinical and clinical trials on intranasal/mucosal coronavirus disease 2019 vaccines.
PIV5: Parainfluenza Virus 5; hPIV2: Human parainfluenza virus 2; NDV: Newcastle disease virus; VSV: Vesicular stomatitis virus; LAIV: Live attenuated influenza vaccine; RSV: Respiratory syncytial virus; COVID-19: Coronavirus disease 2019.
- Citation: Miteva D, Peshevska-Sekulovska M, Snegarova V, Batselova H, Alexandrova R, Velikova T. Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic. World J Virol 2022; 11(5): 221-236
- URL: https://www.wjgnet.com/2220-3249/full/v11/i5/221.htm
- DOI: https://dx.doi.org/10.5501/wjv.v11.i5.221